EyeGate -4.8% after filing for offering

|About: EyeGate Pharmaceuticals (EYEG)|By:, SA News Editor

Clinical-stage firm EyeGate Pharmaceuticals (EYEG -0.5%) is 4.8% lower in postmarket trade after filing an S-1 to offer shares.

The company has registered initially for a maximum offering of $11.5M, with Wedbush PacGrow listed as underwriter.

It says it intends to use proceeds to support operations "including for clinical trials, for working capital and for other general corporate purposes."

Shares are up 28.2% YTD.

Subscribe for full text news in your inbox